(NGSX) NeurogesX – Bull of the Day

November 18th, 2009

NeurogesX (NGSX) received some very good news this week when the U.S. FDA approved Qutenza for the management of postherpetic neuralgia (PHN). Management will now move forward with preparing for the commercial launch during the first half of 2010.

Securing reimbursement and hiring the sales force remain the next biggest hurdles for the company. However, with approval now complete and the financial position solid ($57 million in cash on hand), we remain very position on the NeurogesX story.

We recommend accumulating the stock at today’s level up to $12 per share. Our rating is Outperform.

Zacks Investment Research

More on this topic (What's this?)
I never sleep. Got to hand you these tips. (Penny Stock DD, 12/25/09)
NeurogesX Reports Third Quarter Loss of $.72 per Share (Benzinga, 11/3/10)
Read more on NeurogesX at Wikinvest

Related Posts:

  1. (NGSX) NeurogesX Wins Big FDA Approval for QutenzaFDA Approves NeurogesX’s Qutenza After the market closed on November 16, 2009, NeurogesX (NGSX) announced...
  2. (DOX) Amdocs Limited – Bull of the DayWe maintain our Outperform recommendation for Amdocs Ltd. (DOX), following its strong results for the...
  3. (GOL) Gol Linhas Aereas – Bull of the DayGol Linhas Aereas (GOL) remains better positioned to capitalize on the growth of discount air...
  4. (ONNN) ON Semiconductor- Bull of the DayON Semiconductor (ONNN) is an OEM of primarily analog semiconductors used within a diverse set...
  5. (GRMN) Garmin, Ltd. – Bull of the DayGarmin (GRMN) is an OEM of GPS-based equipment. June quarter results were much better than...
  6. (DOX) Amdocs, Ltd.- Bull of the DayWe maintain our Outperform recommendation for  Amdocs (DOX) following its strong results for the fiscal...


Search Posts by Tag: | | Drug Manufacturers - Other | Healthcare

RSS Feeds by Tag: NeurogesX Inc | NGSX | Drug Manufacturers - Other | Healthcare |

Other Posts by: | RSS Feed for this author